Procept begins Phase II

Procept ( Cambridge, Mass.) began a U.S. Phase II trial of O6-Benzylguanine (BG) chemosensitizing agent with carmustine (BCNU) to treat advanced soft tissue sarcoma. Procept is the biotech subsidiary ...